Raised $2.1B in Series B funding, led by Thrive Capital.
The company said the funding supports accelerate the development and deployment of its AI drug design engine (IsoDDE), expand its pipeline of therapeutic programs toward clinical trials, and scale its global workforce across AI, engineering, and clinical disciplines.